Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
Kathrine Lederballe GrønElizabeth V ArkemaBente GlintborgFrank MehnertMikkel ØstergaardLene DreyerMette NørgaardNiels Steen KroghJohan AsklingMerete Lund Hetlandnull nullPublished in: Annals of the rheumatic diseases (2019)
For patients starting abatacept, rituximab or tocilizumab, differences in baseline characteristics were seen. Numerical differences in IR of SI between drugs were observed. RRs seemed to vary with drug (tocilizumab < abatacept < rituximab) but should be interpreted with caution due to few events and risk of residual confounding.
Keyphrases
- rheumatoid arthritis
- rheumatoid arthritis patients
- diffuse large b cell lymphoma
- disease activity
- newly diagnosed
- juvenile idiopathic arthritis
- hodgkin lymphoma
- chronic lymphocytic leukemia
- end stage renal disease
- healthcare
- palliative care
- emergency department
- quality improvement
- drug induced
- patient reported
- health insurance
- affordable care act